Table 1.
Personal characteristics of the study population.
| Total (%) n = 370 (100%) | Not Pathogenic (%) n = 313 (85%) | Pathogenic (%) n = 57 (15%) | Univariate Analysis p-value | |
|---|---|---|---|---|
| Female | 368 (99) | 311 (99) | 57 (100) | ns |
| Ashkenazi Ethnicity | 4 (01) | 4 (01) | 0 (00) | ns |
| Median age at diagnosis (IQR) | 45 (39–52) | 46 (40–53) | 41 (35–48) | 0.0038 |
| Bilateral Cancers | (07) | 18 (06) | 8 (14) | 0.042 |
| At least 1 NCCN criterion | 332 (90) | 277 (88) | 55 (96) | ns |
| Ductal Carcinoma In Situ | 42 (11) | 37 (12) | 5 (09) | ns |
| Ductal Carcinoma | 253 (68) | 211 (67) | 42 (74) | ns |
| Lobular Carcinoma | 36 (10) | 31 (10) | 5 (09) | ns |
| Histology Others | 22 (06) | 20 (06) | 2 (04) | ns |
| Histology Missing Data | 17 (05) | 14 (04) | 3 (05) | ns |
| HR positive Her2 negative | 236 (64) | 203 (65) | 33 (58) | ns |
| HR positive Her2 positive | 27 (07) | 23 (07) | 04 (07) | ns |
| HR negative Her2 positive | 30 (08) | 27 (09) | 3 (05) | ns |
| HR negative Her2 negative | 63 (17) | 46 (15) | 17 (30) | 0.011 |
| Subtype Missing Data* | 27 (07) | 23 (07) | 4 (07) | ns |
IQR, interquartile range; HR, Hormone Receptors; Her2, Human Epidermal growth factor Receptor 2; ns, not significant; NCCN, National Comprehensive Cancer Network.
*Data do not sum up to 100% due to bilateral cancers.